A note from Gentle Clearing 41
About
Gentle Clearing 41 is an independent resource on ibogaine claims, evidence, and safety. Coral Parable exists to help people distinguish possible short-term effects from unsupported cure claims, with clear uncertainty and respectful context.
Why this exists
Clear context when claims travel fast.
Questions about ibogaine can bring urgency, hope, and a lot of conflicting information. This resource was made for people exploring those questions, along with families and others seeking plainspoken context about claims and risks.
The main guide to the cure claim provides the topic-specific starting point. Here, the focus is our purpose: to make room for evidence, limits, and practical caution without using hype as a shortcut.
Our editorial approach
Sources first, certainty second.
We organize information around questions people actually face: what a claim says, what evidence can and cannot support, where risks or unknowns remain, and what may need professional discussion. Our ways to navigate the resource are designed as orientation, not treatment direction.
When assessing information, we look toward primary literature, trial registries, and official sources rather than testimonials alone. Public trial records are available through the ClinicalTrials.gov study registry, while scientific claims benefit from checking the original record in PubMed’s biomedical literature database.
We also separate information from advice. Regulations, studies, and personal accounts each have different limits, and none should be presented as a guarantee.
How we work
Editorial principles in plain view.
These principles shape how Gentle Clearing 41 presents material and handles uncertainty.
- Evidence before hype
- Clear uncertainty
- Safety awareness
- Plain language
- Respectful context
Independent by design
For readers, not referrals.
Gentle Clearing 41 is an independent information resource. It does not provide medical or legal advice, and it is not a clinic, medical provider, or licensed treatment center. For perspective on how individual drug claims can differ from evidence, the FDA’s drug safety information offers an official reference point.
People may arrive through a broad overview of ibogaine therapy benefits, questions about an ibogaine street name, or searches for ibogaine treatment in Arizona. Wherever the question begins, this resource aims to offer careful context rather than a sales path.
Personal accounts can be meaningful but are not proof of a predictable outcome; readers weighing an ibogaine trip report or considering an ibogaine Mexico clinic can use the same evidence-first lens. That also applies to claims about whether ibogaine works for alcohol: context, uncertainty, and safety belong in the conversation.